...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Translational research: the journal of laboratory and clinical medicine >MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations
【24h】

MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations

机译：MicroRNA 25，microRNA 145和microRNA 210作为生物标志物，用于预测培美曲塞维持治疗对表皮生长因子受体突变或间变性淋巴瘤激酶易位为阴性的肺腺癌患者的疗效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study was conducted to evaluate microRNAs (miRNAs) as biomarkers for use in predicting the efficacy of maintenance therapy with pemetrexed in patients with stage IIIb or IV lung adenocarcinoma and who had already received first-line treatment with pemetrexed plus platinum. Patients who were negative for epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) trans locations were assigned to a pemetrexed group and an observation group. Patients in the pemetrexed group (n = 76) received maintenance treatment with pemetrexed (500 mg/m(2), once every 21 days) plus best supportive care. Patients in the observation group (n = 72) agreed to receive only best supportive care until disease progression. Blood samples were collected from all patients in both groups before treatment and were used to detect expression levels of various miRNAs in serum by the Reverse Transcription-Polymerase Chain Reaction (RT-PCR) method. The expression levels of miR-25, miR-145, and miR-210 were significantly different in the 2 groups of patients. Furthermore, the median progression-free survival (PFS) times for patients in the pemetrexed and observation groups were 4.5 and 2.9 months, respectively. The PFS times among patients in the pemetrexed group varied significantly and were related to patient expression levels of miR-25, miR-145, and miR-210, whereas patients in the observation group showed no differences in PFS time. Our data suggest miR-25, miR-145, and miR-210 as predictors for the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who were negative for EGFR mutations or ALK translocations.
机译：这项研究的目的是评估微RNA（miRNA）作为生物标志物，以预测培美曲塞维持治疗对IIIb或IV期肺腺癌患者和已经接受培美曲塞加铂一线治疗的患者的疗效。表皮生长因子受体（EGFR）突变或间变性淋巴瘤激酶（ALK）反式位点阴性的患者被分为培美曲塞组和观察组。培美曲塞组（n = 76）的患者接受培美曲塞（500 mg / m（2），每21天一次）的维持治疗以及最佳支持治疗。观察组（n = 72）的患者同意仅接受最佳支持治疗，直至疾病进展。治疗前从两组所有患者中采集血样，并通过逆转录聚合酶链反应（RT-PCR）方法检测血清中各种miRNA的表达水平。在两组患者中，miR-25，miR-145和miR-210的表达水平显着不同。此外，培美曲塞组和观察组患者的中位无进展生存（PFS）时间分别为4.5和2.9个月。培美曲塞组患者的PFS时间差异显着，并且与患者miR-25，miR-145和miR-210的表达水平相关，而观察组患者的PFS时间无差异。我们的数据表明，对于EGFR突变或ALK易位阴性的肺腺癌患者，培美曲塞维持治疗的疗效可以通过miR-25，miR-145和miR-210进行预测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号